ClinicalTrials.gg
CompletedNCT03193047Updated Apr 3, 2020Results posted

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

A Phase 2 interventional study of bempedoic acid 180mg and placebo in Hypercholesterolemia, sponsored by Esperion Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-03.

Sponsored by Esperion Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.

Enrollment
16th of 21
59 · median 126
Started
2017
with 3 others
Phase 2
10 of 21
none open now
Registered
13th of 21
by date
Lead sponsor
15 of 21
Esperion Therapeutics, Inc.

Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 16th largest by enrollment, is one of 4 that started in 2017, is one of 10 in phase 2, and was the 13th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About bempedoic acid

bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing bempedoic acid in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this study is to determine if bempedoic acid (ETC-1002) 180mg added to PCSK9 inhibitor (evolocumab) therapy is effective and safe in patients with elevated LDL cholesterol.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • Cholesterol
  • PCSK9
  • Repatha
  • evolocumab
  • LDL-C
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years or legal age of majority depending on regional law
  • Fasting, calculated LDL-C at screening ≥160 mg/dL and following PCSK9i therapy ≥70 mg/dL
  • Men and nonpregnant, nonlactating women

Exclusion criteria

Exclusion Criteria:

  • Heterozygous (HeFH) or Homozygous (HoFH) Familial Hypercholesterolemia
  • Total fasting TG ≥500 mg/dL
  • Renal dysfunction or a glomerulonephropathy; \<30 mL/min/1.73 m2
  • Known cardiovascular disease (CVD), peripheral arterial disease (PAD), or cerebrovascular disease (CD)
  • History of type 1 or type 2 diabetes
  • Uncontrolled hypertension
  • Uncontrolled hypothyroidism
  • Liver disease or dysfunction
  • Gastrointestinal conditions or procedures (including Lap-Band® or gastric bypass)
  • History of hematologic or coagulation disorders
  • History of (except non- basal or squamous cell carcinoma of the skin and cervical carcinoma in situ)
  • Unexplained creatine kinase (CK) >3 ×
  • Use of a cholesterylester transfer protein (CETP) inhibitor in the last 12 months prior to screening, such as: anacetrapib, dalcetrapib, or evacetrapib
  • Pregnant or breast feeding, or planning to become pregnant during treatment and/ or within 30 days after the end of treatment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    bempedoic acid

    Bempedoic acid 180mg tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly

    Drug: bempedoic acid 180mg · Drug: evolocumab

  • Placebo comparator
    placebo

    Matching placebo tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly

    Other: placebo · Drug: evolocumab

Interventions

  • Daily bempedoic acid 180mg tablet in addition to monthly PCSK9i (evolocumab) background therapy

    Also known as: ETC-1002

  • Otherplacebo

    Daily matching placebo tablet in addition to monthly PCSK9i (evolocumab) background therapy

  • Monthly PCSK9i (evolocumab) background therapy

    Also known as: Repatha

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Month 2

    Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the average of the last two non-missing values within Month -1 (Screening Visit 4) and Day 1 (Treatment Visit 1) values (including unscheduled assessments). If only one value was available, then that single value was used at Baseline. Percent change from Baseline was analyzed using analysis of covariance (ANCOVA), with treatment group as a factor and Baseline as a covariate. Missing data were imputed using last observation carried forward (LOCF) (only post-Baseline values were carried forward).

    Time frame: Baseline; Month 2

Secondary outcomes

  1. Percent Change From Baseline in LDL-C at Month 1

    Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the average of the last two non-missing values within Month -1 (Screening Visit 4) and Day 1 (Treatment Visit 1) values (including unscheduled assessments). If only one value was available, then that single value was used at Baseline. Percent change from Baseline was analyzed using ANCOVA, with treatment group as a factor and Baseline as a covariate. Observed data were used for analysis.

    Time frame: Baseline; Month 1

  2. Absolute Change From Baseline in LDL-C at Month 1 and Month 2

    Change from Baseline is calculated as the post-Baseline value minus the Baseline value. Baseline is defined as the average of the Screening Visit 4 and the Day 1 value. If only 1 value is available, then that single value is used as Baseline. Change from Baseline was analyzed using ANCOVA, with treatment group as a factor and Baseline as a covariate. Observed data were used for analysis at Month 1. Missing Month 2 data were handled by LOCF.

    Time frame: Baseline; Month 1 and Month 2

  3. Percent Change From Baseline in Lipid Profile Parameters at Month 1 and Month 2

    Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline apolipoprotein B (apoB) is defined as the Day 1 value. Baseline total cholesterol (TC) and non-high-density lipoprotein cholesterol (non-HDL-C) are defined as the average of the Month -1 (Screening Visit 4) and the Day 1 (Treatment Visit 1) values. If a missing value presented at Month -1 or Day 1, then the last non-missing value prior to the first dose of double-blind study medication (including unscheduled assessments) within Month -1 and Day 1 was used to compute the Baseline measurements. Percent change from Baseline was analyzed using ANCOVA, with treatment group as a factor and Baseline as a covariate. Observed data were used for analysis at Month 1. Missing Month 2 data were handled by LOCF.

    Time frame: Baseline; Month 1 and Month 2

  4. Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Month 1 and Month 2

    Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the Day 1 value. Percent change from Baseline was analyzed using a non-parametric approach. Missing Month 2 data were handled by LOCF. Observed data were used for analysis at Month 1.

    Time frame: Baseline; Month 1 and Month 2

  5. Number of Participants With Any Treatment-emergent Adverse Event (AE) and Treatment-emergent Serious Adverse Event (SAE)

    Treatment-emergent AEs (TEAEs) and SAEs (TESAEs) were reported and defined as any AE that began or worsened after the first dose of investigational medicinal product.

    Time frame: up to Month 2 (until 30 days after last dose)

  6. Number of Participants With Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) >3x the Upper Limit of Normal (ULN) at Month 1 and Month 2

    The number of participants with ALT or AST \>3x ULN was measured.

    Time frame: Month 1 and Month 2

07

Results

Posted Apr 3, 2020

Participant flow

170 participants were screened; out of 170, 59 participants were randomized. One participant never received study medication and withdrew from the study due to the Sponsor's decision.

Participant flow — Overall Study
MilestonePlacebo Plus EvolocumabBempedoic Acid Plus Evolocumab
Started3128
Completed2928
Not completed20
Withdrew: Physician decision10
Withdrew: Participant left state10

Outcome measures

PrimaryPercent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Month 2

Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the average of the last two non-missing values within Month -1 (Screening Visit 4) and Day 1 (Treatment Visit 1) values (including unscheduled assessments). If only one value was available, then that single value was used at Baseline. Percent change from Baseline was analyzed using analysis of covariance (ANCOVA), with treatment group as a factor and Baseline as a covariate. Missing data were imputed using last observation carried forward (LOCF) (only post-Baseline values were carried forward).

Time frame:
Baseline; Month 2
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Month 2
percent changePlacebo Plus EvolocumabBempedoic Acid Plus Evolocumab
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Month 22.783 ± 3.412-27.478 ± 4.310
Statistical analysis
  • Placebo Plus Evolocumab vs Bempedoic Acid Plus Evolocumab · ANCOVA · p = <0.001 · Least squares mean difference: -30.261 · 95% CI -41.324 to -19.199(Bempedoic acid plus evolocumab) minus (placebo plus evolocumab)
SecondaryPercent Change From Baseline in LDL-C at Month 1

Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the average of the last two non-missing values within Month -1 (Screening Visit 4) and Day 1 (Treatment Visit 1) values (including unscheduled assessments). If only one value was available, then that single value was used at Baseline. Percent change from Baseline was analyzed using ANCOVA, with treatment group as a factor and Baseline as a covariate. Observed data were used for analysis.

Time frame:
Baseline; Month 1
Reported as:
Least squares mean · percent change
Percent Change From Baseline in LDL-C at Month 1
percent changePlacebo Plus EvolocumabBempedoic Acid Plus Evolocumab
Percent Change From Baseline in LDL-C at Month 13.172 ± 2.700-32.712 ± 4.385
Statistical analysis
  • Placebo Plus Evolocumab vs Bempedoic Acid Plus Evolocumab · ANCOVA · p = <0.001 · Lease squares mean difference: -35.884 · 95% CI -46.303 to -25.466(Bempedoic acid plus evolocumab) minus (placebo plus evolocumab)
SecondaryAbsolute Change From Baseline in LDL-C at Month 1 and Month 2

Change from Baseline is calculated as the post-Baseline value minus the Baseline value. Baseline is defined as the average of the Screening Visit 4 and the Day 1 value. If only 1 value is available, then that single value is used as Baseline. Change from Baseline was analyzed using ANCOVA, with treatment group as a factor and Baseline as a covariate. Observed data were used for analysis at Month 1. Missing Month 2 data were handled by LOCF.

Time frame:
Baseline; Month 1 and Month 2
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Absolute Change From Baseline in LDL-C at Month 1 and Month 2
milligrams per deciliter (mg/dL)Placebo Plus EvolocumabBempedoic Acid Plus Evolocumab
Month 11.75 ± 3.118-36.51 ± 46.41
Month 2-0.02 ± 3.386-29.92 ± 4.461
Statistical analysis
  • Placebo Plus Evolocumab vs Bempedoic Acid Plus Evolocumab · ANCOVA · p = <0.001 · Least squares mean difference: -38.25 · 95% CI -49.558 to -26.944(Bempedoic acid plus evolocumab) minus (placebo plus evolocumab)
  • Placebo Plus Evolocumab vs Bempedoic Acid Plus Evolocumab · ANCOVA · p = <0.001 · Least squares mean difference: -29.90 · 95% CI -41.176 to -18.626(Bempedoic acid plus evolocumab) minus (placebo plus evolocumab)
SecondaryPercent Change From Baseline in Lipid Profile Parameters at Month 1 and Month 2

Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline apolipoprotein B (apoB) is defined as the Day 1 value. Baseline total cholesterol (TC) and non-high-density lipoprotein cholesterol (non-HDL-C) are defined as the average of the Month -1 (Screening Visit 4) and the Day 1 (Treatment Visit 1) values. If a missing value presented at Month -1 or Day 1, then the last non-missing value prior to the first dose of double-blind study medication (including unscheduled assessments) within Month -1 and Day 1 was used to compute the Baseline measurements. Percent change from Baseline was analyzed using ANCOVA, with treatment group as a factor and Baseline as a covariate. Observed data were used for analysis at Month 1. Missing Month 2 data were handled by LOCF.

Time frame:
Baseline; Month 1 and Month 2
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lipid Profile Parameters at Month 1 and Month 2
percent changePlacebo Plus EvolocumabBempedoic Acid Plus Evolocumab
apo-B at Month 10.547 ± 2.948-26.484 ± 4.175
non-HDL-C at Month 12.077 ± 2.378-29.563 ± 4.031
TC at Month 11.170 ± 1.877-20.770 ± 3.025
apo-B at Month 22.706 ± 2.182-21.763 ± 3.736
non-HDL-C at Month 21.285 ± 2.783-22.960 ± 3.951
TC at Month 20.557 ± 2.009-16.963 ± 3.228
Statistical analysis
  • Placebo Plus Evolocumab vs Bempedoic Acid Plus Evolocumab · ANCOVA · p = <0.001 · Least squares mean difference: -27.031 · 95% CI -37.509 to -16.553(Bempedoic acid plus evolocumab) minus (placebo plus evolocumab)
  • Placebo Plus Evolocumab vs Bempedoic Acid Plus Evolocumab · ANCOVA · p = <0.001 · Least squares mean difference: -24.469 · 95% CI -33.225 to -15.713(Bempedoic acid plus evolocumab) minus (placebo plus evolocumab)
  • Placebo Plus Evolocumab vs Bempedoic Acid Plus Evolocumab · ANCOVA · p = <0.001 · Least squares mean difference: -31.640 · 95% CI -41.116 to -22.163(Bempedoic acid plus evolocumab) minus (placebo plus evolocumab)
  • Placebo Plus Evolocumab vs Bempedoic Acid Plus Evolocumab · ANCOVA · p = <0.001 · Least squares mean difference: -24.246 · 95% CI -33.987 to -14.505(Bempedoic acid plus evolocumab) minus (placebo plus evolocumab)
  • Placebo Plus Evolocumab vs Bempedoic Acid Plus Evolocumab · ANCOVA · p = <0.001 · Least squares mean difference: -21.941 · 95% CI -29.153 to -14.729(Bempedoic acid plus evolocumab) minus (placebo plus evolocumab)
  • Placebo Plus Evolocumab vs Bempedoic Acid Plus Evolocumab · ANCOVA · p = <0.001 · Least squares mean difference: -17.520 · 95% CI -25.201 to -9.839(Bempedoic acid plus evolocumab) minus (placebo plus evolocumab)
SecondaryPercent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Month 1 and Month 2

Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the Day 1 value. Percent change from Baseline was analyzed using a non-parametric approach. Missing Month 2 data were handled by LOCF. Observed data were used for analysis at Month 1.

Time frame:
Baseline; Month 1 and Month 2
Reported as:
Median · percent change
Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Month 1 and Month 2
percent changePlacebo + EvolocumabBempedoic Acid + Evolocumab
hs-CRP at Month 110.658 (-36.488 to 66.374)-23.349 (-57.857 to 5.128)
hs-CRP at Month 2-1.623 (-39.445 to 26.531)-34.444 (-57.599 to -7.083)
Statistical analysis
  • Placebo + Evolocumab vs Bempedoic Acid + Evolocumab · Wilcoxon rank sum test · p = 0.046 · Median treatment difference: -32.479 · 95% CI -70.524 to -2.339The median treatment difference (location shift) and the 95% confidence limits are from Hodges-Lehmann estimates.
  • Placebo + Evolocumab vs Bempedoic Acid + Evolocumab · Wilcoxon rank sum test · p = 0.029 · Median treatment difference: -28.512 · 95% CI -51.455 to -3.930The median treatment difference (location shift) and the 95% confidence limits are from Hodges-Lehmann estimates.
SecondaryNumber of Participants With Any Treatment-emergent Adverse Event (AE) and Treatment-emergent Serious Adverse Event (SAE)

Treatment-emergent AEs (TEAEs) and SAEs (TESAEs) were reported and defined as any AE that began or worsened after the first dose of investigational medicinal product.

Time frame:
up to Month 2 (until 30 days after last dose)
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (AE) and Treatment-emergent Serious Adverse Event (SAE)
ParticipantsPlacebo + EvolocumabBempedoic Acid + Evolocumab
Any TEAE79
TEAEs related to IMP11
TEAEs related to evolocumab10
TESAEs01
TESAEs related to IMP00
TESAEs related to evolocumab00
Deaths00
Discontinuation of IMP due to TEAE00
Mild TEAEs54
Moderate TEAEs24
Severe TEAEs01
SecondaryNumber of Participants With Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) >3x the Upper Limit of Normal (ULN) at Month 1 and Month 2

The number of participants with ALT or AST \>3x ULN was measured.

Time frame:
Month 1 and Month 2
Reported as:
Count of participants · Participants
Number of Participants With Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) >3x the Upper Limit of Normal (ULN) at Month 1 and Month 2
ParticipantsPlacebo Plus EvolocumabBempedoic Acid Plus Evolocumab
ALT, Month 100
ALT, Month 200
AST, Month 100
AST, Month 200

Adverse events

Collected over up to Month 2 (until 30 days after last dose). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Plus Evolocumab0/30 (0%)0/30 (0%)7/30 (23.3%)
Bempedoic Acid Plus Evolocumab0/28 (0%)1/28 (3.6%)8/28 (28.6%)
Most frequent serious events
Most frequent serious events
EventPlacebo Plus EvolocumabBempedoic Acid Plus Evolocumab
InfluenzaInfections and infestations0/301/28
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPlacebo Plus EvolocumabBempedoic Acid Plus Evolocumab
DyspepsiaGastrointestinal disorders0/301/28
DysphagiaGastrointestinal disorders0/301/28
Urinary tract infectionInfections and infestations1/301/28
GoutMetabolism and nutrition disorders0/301/28
ArthralgiaMusculoskeletal and connective tissue disorders0/301/28
DizzinessNervous system disorders0/301/28
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/301/28
DermatitisSkin and subcutaneous tissue disorders0/301/28
HyperhidrosisSkin and subcutaneous tissue disorders0/301/28
Injection site reactionGeneral disorders1/300/28

Baseline characteristics

Safety population included all randomized participants who received at least 1 dose of study medication. Participants in this group were included in the treatment group that they received, regardless of their randomized treatment.

Age, Continuous
Age, Continuous(years)Placebo Plus EvolocumabBempedoic Acid Plus EvolocumabTotal
Mean58.4 ± 11.1662.0 ± 9.3660.1 ± 10.40
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Plus EvolocumabBempedoic Acid Plus EvolocumabTotal
Female152136
Male15722
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo Plus EvolocumabBempedoic Acid Plus EvolocumabTotal
Black or African American246
White282452
Baseline Low-Density Lipoprotein Cholesterol (L-DLC) Values
Baseline Low-Density Lipoprotein Cholesterol (L-DLC) Values(milligrams per deciliter (mg/dL))Placebo Plus EvolocumabBempedoic Acid Plus EvolocumabTotal
Mean104.12 ± 32.121102.09 ± 28.982103.14 ± 30.395
Baseline Total Cholesterol (TC) and Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) Values
Baseline Total Cholesterol (TC) and Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) Values(mg/dL)Placebo Plus EvolocumabBempedoic Acid Plus EvolocumabTotal
TC190.33 ± 39.387186.20 ± 38.343188.34 ± 38.601
non-HDL-C132.95 ± 36.599129.68 ± 36.301131.37 ± 36.172
Baseline Apolipoprotein B (apoB) Values
Baseline Apolipoprotein B (apoB) Values(mg/dL)Placebo Plus EvolocumabBempedoic Acid Plus EvolocumabTotal
Mean87.9 ± 23.8087.5 ± 27.1387.7 ± 25.29
Baseline High-Sensitivity C-Reactive Protein (hs-CRP) Values
Baseline High-Sensitivity C-Reactive Protein (hs-CRP) Values(milligrams per Liter)Placebo Plus EvolocumabBempedoic Acid Plus EvolocumabTotal
Median2.090 (1.120 to 4.690)3.125 (1.270 to 4.590)2.340 (1.170 to 4.640)
08

Study locations

1 site
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
09

References and documents

Publications

  • Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, Birch CM, Smith BK, Filippov S, Groot PHE, Steinberg GR, Lalwani ND. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016 Nov 28;7:13457. doi: 10.1038/ncomms13457. PubMed 27892461 ↗
  • Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a. Epub 2013 Nov 12. No abstract available. Erratum In: Circulation. 2014 Jun 24;129(25 Suppl 2):S46-8. Circulation. 2015 Dec 22;132(25):e396. doi: 10.1161/CIR.0000000000000346. PubMed 24222016 ↗
  • Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W; Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001 Sep 4;104(10):1108-13. doi: 10.1161/hc3501.095214. PubMed 11535564 ↗
  • Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003 Apr 2;289(13):1681-90. doi: 10.1001/jama.289.13.1681. PubMed 12672737 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Jan 2018, 9 months.

Results were first posted in Apr 2020, 2 years 2 months after primary completion. A results delay was requested in Apr 2018.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 9 months is close to that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2017
First posted
Jun 20, 2017
StartActual
Apr 7, 2017
Primary completionActual
Jan 29, 2018
CompletionActual
Feb 19, 2018
Results delay requested
Apr 30, 2018
Results first posted
Apr 3, 2020
Last update
Apr 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03193047
Responsible party
Sponsor
First posted
Jun 20, 2017
Start date
Apr 7, 2017
Primary completion
Jan 29, 2018
Completion
Feb 19, 2018
Results posted
Apr 3, 2020
Last update
Apr 3, 2020

Study contacts

Ron Haberman, MD
study director · Esperion Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bempedoic acid

Start the discussion